We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency (EMA) is now reviewing Johnson & Johnson’s (J&J) conditional marketing authorization application for its COVID-19 vaccine, a single-dose inoculation that would help to simplify the EU’s vaccination efforts. Read More
Breyanzi (lisocabtagene maraleucel) will be manufactured for each individual patient at the company’s cellular immunotherapy manufacturing facility in Bothell, Wash. Read More
The agency approved the label change after concluding that an acceptable amount of overfill will remain in each vial after extracting six doses. Read More